Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
| ▸ | EBP | Q15125 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21576147 | 0.83 | FDPS (0.34) | FDPSLMNAPLA2G1BPLA2G2ADNM1 | |
| SCHEMBL25748484 | 0.83 | FDPS (0.34) | FDPSLMNAPLA2G1BPLA2G2ADNM1 | |
| SCHEMBL23733438 | 0.76 | EBP (0.38) | OPRM1FDPSLMNADNM1SMPD1 | |
| SCHEMBL23733443 | 0.76 | EBP (0.38) | OPRM1FDPSLMNADNM1SMPD1 | |
| SCHEMBL24555502 | 0.76 | EBP (0.38) | OPRM1FDPSLMNADNM1EBP | |
| SCHEMBL11460136 | 0.76 | CA1 (0.33) | FDPSSMPD1EBPSIGMAR1GUSB | |
| SCHEMBL18612411 | 0.76 | FDPS (0.34) | FDPSLMNADNM1SMPD1EBP | |
| SCHEMBL23765250 | 0.75 | FDPS (0.36) | OPRM1FDPSLMNADNM1EBP | |
| SCHEMBL18625032 | 0.75 | FDPS (0.36) | OPRM1FDPSLMNADNM1EBP | |
| SCHEMBL19251213 | 0.75 | GNAI3 (0.40) | OPRM1FDPSLMNAPLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242508-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242508-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | OPRM1 3072/4885FDPS 1960/4885LMNA 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.